| Followers | 19 |
| Posts | 6615 |
| Boards Moderated | 1 |
| Alias Born | 05/23/2019 |
Saturday, February 22, 2025 10:46:11 AM
WQLF SAYS: These options were not granted in 2021,2022 and 2023.
The following for 2025 options.
Joseph Dowling 3,000,000 Options
Over 36 months is 83,333 shares per month to be exercised. 83,333 multiplied by $.04 equals $3,333 per month. The shares added by the CEO, CFO and the two directors will cause dilution. The effect on their vesting if they sell on a monthly period in my opinion will not cause a downward effect on the price of the shares.
Joseph Dowling 3,000,000 Share Option and the 2,350,000 option shares for Joerg Grasser.
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from February 18, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after the termination of service.“
Here is the explanation for the two board of directors. 500,000 option shares for both directors.
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable on April 30, 2026, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service.“
This is a schedule of shares granted in June 20, 2024 with explanation for Dowling, Grasser. McCorkle, and Corroon
Joseph Dowling
https://www.sec.gov/Archives/edgar/data/1510964/000095017024076906/xslF345X05/ownership.xml
Joerg Grasser
https://www.sec.gov/Archives/edgar/data/1763727/000095017024076912/xslF345X05/ownership.xml
For Dowling and Grasser
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from June 20, 2024, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service.“
William McCorkle
https://www.sec.gov/Archives/edgar/data/1953074/000095017024076938/xslF345X05/ownership.xml
James Michael Corroon Jr.
https://www.sec.gov/Archives/edgar/data/1940094/000095017024076934/xslF345X05/ownership.xml
Explanation of Responses:
For Both McCorkle and Corroon.
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable on April 30, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service”.
2025 Share Options
Thomas@yahoo
Re: Wolf-man jack post# 83760
Friday, 02/21/2025 5:11:01 AM
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024328/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024329/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024327/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024330/ownership.html
Bullish
BULLISH
The following for 2025 options.
Joseph Dowling 3,000,000 Options
Over 36 months is 83,333 shares per month to be exercised. 83,333 multiplied by $.04 equals $3,333 per month. The shares added by the CEO, CFO and the two directors will cause dilution. The effect on their vesting if they sell on a monthly period in my opinion will not cause a downward effect on the price of the shares.
Joseph Dowling 3,000,000 Share Option and the 2,350,000 option shares for Joerg Grasser.
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from February 18, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after the termination of service.“
Here is the explanation for the two board of directors. 500,000 option shares for both directors.
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable on April 30, 2026, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service.“
This is a schedule of shares granted in June 20, 2024 with explanation for Dowling, Grasser. McCorkle, and Corroon
Joseph Dowling
https://www.sec.gov/Archives/edgar/data/1510964/000095017024076906/xslF345X05/ownership.xml
Joerg Grasser
https://www.sec.gov/Archives/edgar/data/1763727/000095017024076912/xslF345X05/ownership.xml
For Dowling and Grasser
Explanation of Responses:
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from June 20, 2024, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service.“
William McCorkle
https://www.sec.gov/Archives/edgar/data/1953074/000095017024076938/xslF345X05/ownership.xml
James Michael Corroon Jr.
https://www.sec.gov/Archives/edgar/data/1940094/000095017024076934/xslF345X05/ownership.xml
Explanation of Responses:
For Both McCorkle and Corroon.
1. The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable on April 30, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service”.
2025 Share Options
Thomas@yahoo
Re: Wolf-man jack post# 83760
Friday, 02/21/2025 5:11:01 AM
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024328/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024329/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024327/ownership.html
https://ir.cvsciences.com/sec-filings-email/content/0000950170-25-024330/ownership.html
Bullish
BULLISH
Bullish
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:10:09 PM
- CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results • ACCESS Newswire • 05/14/2026 08:00:00 PM
- CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 • ACCESS Newswire • 05/12/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
